Evidence map›Paper›PMID 42074000›Full record

ArticleInternational journal of molecular sciences2026

10-epi-Protectin DX and Resolvin D5

Suyeon Kim, Uijin Kim, Nahyun Kim, Tae-Eui Lee, Jin Lee, Deok-Kun Oh, Ha Youn Shin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Suyeon KimDepartment of Biomedical Science and Engineering, Konkuk University, Seoul 05029, Republic of Korea.ORCID 0000-0003-4172-7559
Uijin KimDepartment of Biomedical Science and Engineering, Konkuk University, Seoul 05029, Republic of Korea.ORCID 0009-0001-9894-4362
Nahyun KimDepartment of Biomedical Science and Engineering, Konkuk University, Seoul 05029, Republic of Korea.ORCID 0009-0008-8109-7276
Tae-Eui LeeDepartment of Bioscience and Biotechnology, Konkuk University, Seoul 05029, Republic of Korea.ORCID 0000-0001-8629-1125
Jin LeeDepartment of Bioscience and Biotechnology, Konkuk University, Seoul 05029, Republic of Korea.
Deok-Kun OhDepartment of Bioscience and Biotechnology, Konkuk University, Seoul 05029, Republic of Korea.ORCID 0000-0002-6886-7589
Ha Youn ShinDepartment of Biomedical Science and Engineering, Konkuk University, Seoul 05029, Republic of Korea.ORCID 0000-0002-8553-2107

Funding

Konkuk University 2025
6 · The paper itself

Abstract

Sepsis is a life-threatening syndrome driven by dysregulated immune activation and multi-organ dysfunction, with limited effective therapies. Oxylipins are endogenous lipid mediators that promote the resolution of inflammation and tissue repair, yet their therapeutic potential in systemic inflammatory diseases remains incompletely understood. In this study, we evaluated the effects of two oxylipins, 10-epi-Protectin DX (10-epi-PDX) and Resolvin D5

Indexed as

Anti-Inflammatory AgentsDocosahexaenoic AcidsEndotoxemiaInflammationAnimalsDisease Models, AnimalKidneyLipopolysaccharidesLiverLungMaleMiceMice, Inbred C57BLSpecialized Pro-Resolving MediatorsAnti-Inflammatory AgentsDocosahexaenoic AcidsLipopolysaccharides10-epi-Protectin DX (10-epi-PDX)endotoxemiainflammationlipopolysaccharide (LPS)oxylipinsResolvin D5n-3 DPA (RvD5n-3 DPA)sepsis

Identifiers

PMID42074000
PMCPMC13116450

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.